Jpmorgan Chase & CO Iveric Bio, Inc. Transaction History

Jpmorgan Chase & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$26.24 - $39.63 $9.95 Million - $15 Million	-379,019 Reduced 48.46%	403,077 $15.9 Million
Q1 2023 May 18, 2023	BUY	$18.67 - $24.56 $3.14 Million - $4.12 Million	167,934 Added 27.34%	782,096 $19 Million
Q1 2023 May 11, 2023	SELL	$18.67 - $24.56 $1.59 Million - $2.09 Million	-84,931 Reduced 12.15%	614,162 $14.9 Million
Q4 2022 Feb 13, 2023	SELL	$17.24 - $23.95 $1.91 Million - $2.66 Million	-110,940 Reduced 13.7%	699,093 $15 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $1.07 Million - $2.11 Million	-113,564 Reduced 12.3%	810,033 $14.5 Million
Q2 2022 Aug 11, 2022	BUY	$9.12 - $18.9 $3.48 Million - $7.21 Million	381,732 Added 70.45%	923,597 $8.89 Million
Q1 2022 May 11, 2022	BUY	$12.15 - $16.83 $5.59 Million - $7.74 Million	460,137 Added 563.01%	541,865 $9.12 Million
Q4 2021 Feb 10, 2022	BUY	$13.83 - $18.78 $490,397 - $665,920	35,459 Added 76.64%	81,728 $1.37 Million
Q3 2021 Nov 12, 2021	BUY	$7.07 - $17.5 $327,121 - $809,707	46,269 New	46,269 $751,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.